立即開始
Investor4321

AVEO Could Rise 200+% On The 15th

Investor4321  
NASDAQ:AVEO   None
Fundamental Analysis
5
2
fundamental
This company is releasing data for phase one clinical trial data for a cancer treatment drug. The risk is high, but if the data is good, The stock could rise 200+%.

相關想法

Investor4321
$PENN Swing Idea, Target $130
免責聲明

這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。